Background: Neoadjuvant endocrine therapy presents an important downstaging option with lower toxicity than neoadjuvant chemotherapy in oestrogen receptor (ER)-positive early breast cancer. Meta-analysis of the effects of neoadjuvant endocrine therapy on surgical outcomes across randomized clinical trials (RCTs) and cohort studies has not previously been performed.
Methods: A systematic review and meta-analysis was performed to evaluate the effect of neoadjuvant endocrine therapy on surgical outcomes (PROSPERO (international prospective register of systematic reviews, 2020)) compared with surgery followed by adjuvant endocrine therapy. PubMed and EMBASE were searched to identify RCT and cohort studies between 1946 and 27 March 2024. Two independent reviewers manually screened the identified records and extracted the data. Risk of bias was assessed using the Cochrane Collaboration tools and random-effects meta-analysis was done with ReviewManager.
Results: The search identified 2390 articles eligible for screening. The review included 20 studies (12 cohort and 8 RCTs); 19 were included in the meta-analysis with a total of 6382 patients. Overall, neoadjuvant endocrine therapy was associated with a lower mastectomy rate compared with surgery first (risk ratio (RR) 0.53, 95% c.i. 0.44 to 0.64). Subgroup analysis showed similar improvement in the mastectomy rate in the neoadjuvant endocrine therapy group versus control group irrespective of study type (RCT: RR 0.58, 95% c.i. 0.50 to 0.66; cohorts: RR 0.48, 95% c.i. 0.33 to 0.70). There was no difference in the mastectomy rate by duration of neoadjuvant endocrine therapy (more than 4 months: RR 0.57, 95% c.i. 0.42 to 0.78; 4 months or less than 4 months: RR 0.52, 95% c.i. 0.43 to 0.64). Most of the studies were characterized by moderate-quality evidence with significant heterogeneity.
Conclusion: Neoadjuvant endocrine therapy is associated with a reduction in mastectomy rate. Given the moderate methodological quality of previous studies, further RCTs are required.
Registration Id: CRD42020209257.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11488384 | PMC |
| http://dx.doi.org/10.1093/bjsopen/zrae100 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An associate of suspicious axillary node and sentinel node in breast cancer to minimizing axillary surgery, prospective cohort study.
Ann Med Surg (Lond)
December 2024
Department of Surgery, Breast and Endocrine Surgery Unit, Faculty of Medicine Ramathibodi Hospital, Mahidol University.
Background: Arm morbidity and postoperative complications following sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) are common problems in patients with breast cancer. The de-escalating axillary surgery is increasing; however, there is a lack of patients with suspicious nodes. This study aimed to reduce the need for SLNB in suspicious lymph node cases.
View Article and Find Full Text PDFBreast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03.
Ann Surg Oncol
December 2024
Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Background: This study aims to identify factors predicting recurrence and unfavorable prognosis in cN+ patients who have undergone sentinel lymph node biopsy (SLNB) following neoadjuvant chemotherapy (NAC).
Methods: The retrospective multi-centre "MF18-02" and the prospective multi-centre cohort registry trial "MF18-03" (NCT04250129) included patients with cT1-4N1-3M0 with SLNB+/- axillary lymph node dissection (ALND) post-NAC.
Results: A total of 2407 cN+ patients, who later achieved cN0 status after NAC and subsequently underwent SLNB, were studied.
Characteristics, treatment patterns and survival of patients with high-risk early hormone receptor-positive breast cancer in French real-world settings: an exploratory study of the CANTO cohort.
ESMO Open
December 2024
Department of Medical Oncology, Gustave Roussy, Villejuif, France; CESP, INSERM U1018, Université Paris-Saclay, Villejuif, France. Electronic address:
Article Synopsis
- Patients with high-risk hormone receptor-positive, HER2-negative breast cancer (HR+ BC) show a significant risk of relapse, prompting the need for additional treatment strategies.
- The study analyzed data from the CANcer TOxicities (CANTO) study, involving patients between 2012 and 2022, categorizing them based on various unfavorable features indicating high risk.
- Results indicated that most patients underwent (neo)adjuvant chemotherapy and endocrine therapy; however, many discontinued treatment due to adverse events, with a 5-year survival rate reflecting the need for ongoing management in this patient group.
Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study.
ESMO Open
December 2024
Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Reveal Genomics, Barcelona, Spain; Institute of Cancer and Blood Disorders, Hospital Clinic of Barcelona, Barcelona, Spain; Institute of Oncology (IOB)-Hospital Quirón Salud, Barcelona, Spain. Electronic address:
Background: Predictors of response to neoadjuvant chemotherapy (NACT) and endocrine therapy (NET) in hormone receptor-positive (HoR+)/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) are required. Also, pathological and molecular changes induced by both strategies and their impact on patients' outcomes have not been reported so far.
Patients And Methods: In a cohort of 186 patients with early-stage HoR+/HER2-negative BC treated with NACT or NET, we assessed the association of baseline main clinicopathological features and PAM50 gene expression (GE), intrinsic subtypes (IS) and risk-of-relapse (ROR-P) score with pathological outcomes according to treatment strategy.
Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial.
JAMA Netw Open
November 2024
Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Article Synopsis
- In early-stage breast cancer (EBC) patients, there is a need for biomarkers to predict the risk of late recurrence and the benefit from extended endocrine therapy (EET), specifically using the MammaPrint 70-gene assay to identify low-risk tumors.
- The study analyzed postmenopausal women with hormone receptor-positive EBC from the IDEAL trial to see if the MammaPrint assay could help decide between 2.5 years and 5 years of treatment with letrozole.
- Results showed that patients with low-risk tumors had a significant benefit of 10.1% for distant recurrence with longer treatment, while no significant benefits were found for high-risk or ultralow risk patients regarding treatment duration
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!